scholarly journals High Incidence of Hepatitis C Virus (HCV) Infection among an Urban Emergency Department (ED) Patients. 2003–2016.

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S195-S195
Author(s):  
Anuj Patel ◽  
Richard Rothman ◽  
David Thomas ◽  
Yu-Hsiang Hsieh
Keyword(s):  
Emergency Department ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hcv Infection ◽  
High Incidence ◽  
Urban Emergency Department

scholarly journals P120: Rapid hepatitis C virus screening and diagnostic testing for high-risk patients in an urban emergency department: a pilot project

CJEM ◽  
2018 ◽  
Vol 20 (S1) ◽  
pp. S99-S99
Author(s):  
K. Ragan ◽  
A. Pandya ◽  
N. Collins ◽  
M. Swain ◽  
T. Holotnak
Keyword(s):  
Emergency Department ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
High Risk ◽  
Hcv Infection ◽  
High Risk Patients ◽  
Risk Patients ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Urban Emergency Department

Introduction: Hepatitis C virus (HCV) infection represents a significant public health problem in Canada and it is estimated that nearly half of individuals with chronic hepatitis C infection are unaware of their disease status. Previous studies of urban emergency department (ED) based screening programs have shown a prevalence ranging from 7.3 to 26% in high risk patients presenting to the ED . The advent of new treatment regimens with high rates of virologic cure strengthens the case for identifying the optimal setting for screening and testing individuals who may benefit from treatment. The proposed pilot project of ED-based screening for hepatitis C virus will aim to determine the prevalence of undiagnosed HCV infection and to link patients with chronic HCV infection to appropriate specialized follow-up care. Methods: We will be conducting a prospective cohort study of patients presenting to an urban emergency department between March and May 2018. Patients will be screened using high risk criteria for HCV infection as per national guidelines. Eligible patients will be offered and consented for a rapid point of care antibody test. Individuals with a positive antibody screen will have confirmatory testing and be linked to hepatology follow-up. The primary outcome will be the prevalence of hepatitis C virus among tested patients. Secondary outcomes will include the proportion of high risk patients without a primary care MD or access to alternate care settings where screening may occur, as well as the proportion of HCV-positive patients who are successfully linked to care. Results: We expect to screen approximately 2000 participants during the study period leading to an estimated 400 rapid antibody tests. Based on published results from other centres, we estimate that a significant proportion of screened patients will test positive for chronic HCV infection ( > 10%). Descriptive analyses will be performed for all variables using proportions with 95% confidence intervals. Conclusion: To our knowledge, no emergency department in Canada has undertaken protocoled HCV screening using rapid antibody testing in the ED. Results will inform the future development of integrated ED-based screening programs in novel settings more likely to be accessed by the at-risk population. Linking patients with chronic HCV infection to appropriate care will decrease the number of individuals developing HCV-related cirrhosis and hepatocellular carcinoma, thereby improving patient outcomes and reducing the future impact on our health care system.

scholarly journals Results of a Rapid Hepatitis C Virus Screening and Diagnostic Testing Program in an Urban Emergency Department

2016 ◽  
Vol 67 (1) ◽  
pp. 119-128 ◽  
Author(s):  
Douglas A.E. White ◽  
Erik S. Anderson ◽  
Sarah K. Pfeil ◽  
Tarak K. Trivedi ◽  
Harrison J. Alter
Keyword(s):  
Emergency Department ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Diagnostic Testing ◽  
Testing Program ◽  
Urban Emergency Department ◽  
Virus Screening

scholarly journals Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department

2016 ◽  
Vol 62 (9) ◽  
pp. 1059-1065 ◽  
Author(s):  
Yu-Hsiang Hsieh ◽  
Richard E. Rothman ◽  
Oliver B. Laeyendecker ◽  
Gabor D. Kelen ◽  
Ama Avornu ◽  
...  
Keyword(s):  
Emergency Department ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Disease Control ◽  
Control And Prevention ◽  
Centers For Disease Control ◽  
Virus Testing ◽  
Urban Emergency Department

scholarly journals Prevalence of Hepatitis C Virus Infection Identified from Non-Targeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department

2021 ◽  
Author(s):  
J Daniel Moore ◽  
James Galbraith ◽  
Roger Humphries ◽  
Jennifer R Havens
Keyword(s):  
Emergency Department ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Screening Program ◽  
Clinical Care ◽  
White Male ◽  
Hcv Infection ◽  
Primary Study ◽  
Opt Out ◽  
Hcv Testing

Abstract Study Objectives We describe the initial results of an adult academic emergency department (ED) non-targeted hepatitis C virus (HCV) screening program serving Appalachia, which is disproportionately affected by the opioid epidemic. Methods The study was a retrospective screening study of ED systematic, non-targeted, opt-out HCV testing outcomes from July 2018 through September 2020. Eligibility requirements for “non-targeted” HCV testing included: adults (greater than 17 years), verbally able to communicate, receiving blood work already as part of routine clinical care, and not opting-out of testing. For eligible individuals who did not opt-out of testing, an HCV antibody (Ab) test was performed. Reactive Ab tests were confirmed with reflexive HCV ribonucleic acid (RNA) testing. The primary study outcome was the characterization of HCV Ab and RNA prevalence. Results There were 75,722 unique adult visitors during the period studied. Of these, 54,931 individuals were verbally engaged regarding testing and did not opt-out. A total of 34,848 individuals received HCV Ab testing, with 3,665 patients (10.5%) having reactive results. RNA confirmatory testing was reflexively performed in all Ab positive patients, with 1,601 (50.3%) positive. The majority of HCV Ab and RNA positive patients were young, born after 1965, and were more likely to be White, male, Medicaid insured, and report a history of injection drug use. Conclusion ED non-targeted, opt-out testing can identify a high prevalence of HCV infection among adult visitors. HCV infection was disproportionately high among younger, White individuals, likely reflecting the escalating syndemic of opioid injection and HCV transmission in Appalachia.

Position Paper on Treatment of Hepatitis C in Romania, 2017. Part One

2017 ◽  
Vol 26 (2) ◽  
pp. 171-181 ◽  
Author(s):  
Liana Gheorghe ◽  
Ioan Sporea ◽  
Speranţa Iacob ◽  
Roxana Şirli ◽  
Anca Trifan ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Limit Of Detection ◽  
Position Paper ◽  
Hcv Infection ◽  
Fixed Dose ◽  
Diagnostic Tools ◽  
End Stage Liver Disease ◽  
End Stage

Background & Aims: Hepatitis C Virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%. New treatments became available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country.Methodology: A group of recognized experts was created who screened the available literature and the major available guidelines. A list of items requiring attention has been created. These items were discussed and rated. Decisions were taken by consensus.Recommendations: We present here the first of the two parts of our Society’s recommendations for chronic HCV infection treatment. An agreement was reached regarding the diagnostic tools, the assessment of severity and the up-dated therapy schedules.Conclusions: This Position Paper represents a guide for the assessment and the therapy of HCV infection. The recommendations are in concordance with other guidelines but are applied to the real-life conditions in this country.Abbreviations: DAAs: Direct-acting antivirals; DDIs: Drug-drug interactions; ESLD: End-stage liver disease; ESRD: End-stage renal disease; eGFR: Estimated glomerular filtration rate; EASL: European Association for the Study of the Liver; EMA: European Medicines Agency; FDA: US Food and Drug Administration; FDC: Fixed-dose combination; GT: Genotype; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; LT: Liver transplantation; LLD: Lower limit of detection; MELD score: Mayo-Clinic End-Stage Liver Disease score; ANMDM: National Agency of Medicines and Medical Devices; PPIs: Proton pump inhibitors; PWID: People who inject drugs; RCT: Randomized controlled trial; RDT: Rapid diagnostic test; RAS: Resistance-associated substitution; SRGH: Romanian Society of Gastroenterology and Hepatology; SAE: serious adverse events; SPC: Summary of Product Characteristics; SVR: Sustained virologic response.

Sign in / Sign up

Export Citation Format

Share Document